This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-15 and is reviewed periodically as new material appears.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Hygroscopic; let the vial equilibrate before opening |
| Solubility | Freely soluble in water and aqueous buffers | Working solutions are often prepared between 0.1 and 1 mg per mL |
| Typical storage temperature | At or below 20 degrees below zero Celsius | Desiccant and sealed vials reduce moisture uptake |
| Routine purity assay | Reversed-phase HPLC with ultraviolet detection | Result reported as percentage of total peak area |
| Identity check | Mass spectrometry with amino acid analysis | Observed mass is compared with the calculated value |
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Insulin is synthesized as an inactive precursor molecule, a 110 amino acid-long protein called preproinsulin. Preproinsulin is translated directly into the rough endoplasmic reticulum (RER), where its signal peptide is removed by signal peptidase to form proinsulin. As the proinsulin folds, opposite ends of the protein, called the "A-chain" and the "B-chain", are fused together with three disulfide bonds. Folded proinsulin then transits through the Golgi apparatus and is packaged into specialized secretory vesicles, or granules. In the granule, proinsulin is cleaved by proprotein convertase 1/3 and proprotein convertase 2, removing the middle part of the protein, called the "C-peptide". Finally, carboxypeptidase E removes two pairs of amino acids from the protein's ends, resulting in active insulin – the insulin A- and B- chains, now connected with two disulfide bonds. The resulting mature insulin is packaged inside mature granules waiting for metabolic signals (such as leucine, arginine, glucose and mannose) and vagal nerve stimulation to be exocytosed from the cell into the circulation. Insulin and its related proteins have been shown to be produced inside the brain, and reduced levels of these proteins are linked to Alzheimer's disease. Insulin release is stimulated also by beta-2 receptor stimulation and inhibited by alpha-1 receptor stimulation. In addition, cortisol, glucagon and growth hormone antagonize the actions of insulin during times of stress. Insulin also inhibits fatty acid release by hormone-sensitive lipase in adipose tissue.
In the United States, heroin is not accepted as medically useful. Its classification as a Schedule I drug means it has "no currently accepted medical use and a high potential for abuse." Under the generic name diamorphine, heroin is prescribed as a strong pain medication in the United Kingdom, where it is administered via oral, subcutaneous, intramuscular, intrathecal, intranasal or intravenous routes. It may be prescribed for the treatment of acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain and chronic pain, including end-stage terminal illnesses. In other countries it is more common to use morphine or other strong opioids in these situations. The UK's National Institute for Health and Clinical Excellence has produced guidance on the management of caesarean section, which recommends the use of intrathecal or epidural diamorphine for post-operative pain relief. For women who have had intrathecal opioids including diamorphine, there should be a minimum hourly observation of respiratory rate, sedation and pain scores for at least 12 hours if risk factors for respiratory depression are present. Women should be offered diamorphine (up to 0.3mg intrathecally) for intra- and postoperative analgesia because it reduces the need for supplemental analgesia after a caesarean section. Epidural diamorphine (up to 3mg) is a suitable alternative. Diamorphine continues to be widely used in palliative care in the UK, where it is commonly given by the subcutaneous route, often via a syringe driver if patients cannot easily swallow morphine solution.
Silicon single crystals may be produced today in commercial facilities with extremely high purity and with few lattice defects. This method defined the Avogadro constant as the ratio of the molar volume, Vm, to the atomic volume Vatom:
Sources: en.wikipedia.org
With the exception of dual flow (see below) CCC, most countercurrent chromatography modes of operation have a stationary phase and a mobile phase. Even in this situation, countercurrent flows occur within the instrument column. Several researchers have proposed renaming both CCC & CPC to liquid-liquid chromatography, but others feel the term "countercurrent" itself is a misnomer. Unlike column chromatography and HPLC, countercurrent chromatography operators can inject large volumes relative to column volume. Typically 5 to 10% of coil volume can be injected. In some cases this can be increased to as high as 15 to 20% of the coil volume. Typically, most modern commercial CCC and CPC can inject 5 to 40 g/L capacity. The range is so large, even for a specific instrument, let alone all instrument options, as the type of target, matrix and available biphasic solvent vary so much. Approximately 10 g/L would be a more typical value, that the majority of applications could use as a base value. The countercurrent separation starts with choosing an appropriate biphasic solvent system for the desired separation. A wide array of biphasic solvent mixtures are available to the CCC practitioner including the combination n-hexane (or heptane), ethyl acetate, methanol and water in different proportions. This basic solvent system is sometimes referred to as the HEMWat solvent system. The choice of solvent system may be guided by perusal of the CCC literature. The familiar technique of thin layer chromatography may also be employed to determine an optimal solvent system.
== Factor XIII deficiency == Factor XIII deficiency, while generally rare, does occur, with Iran having the highest global incidence of the disorder with 473 cases. The city of Khash, located in Sistan and Balochistan provinces, has the highest incidence in Iran, with a high rate of consanguineous marriage.
Compounds and their metabolites need to be removed from the body via excretion, usually through the kidneys (urine) or in the feces. Unless excretion is complete, accumulation of foreign substances can adversely affect normal metabolism. There are three main sites where drug excretion occurs. The kidney is the most important site and it is where products are excreted through urine. Biliary excretion or fecal excretion is the process that initiates in the liver and passes through to the gut until the products are finally excreted along with waste products or feces. The last main method of excretion is through the lungs (e.g. anesthetic gases). Excretion of drugs by the kidney involves 3 main mechanisms:
=== Transgenic plant and animals === In recent years, expression vectors have been used to introduce specific genes into plants and animals to produce transgenic organisms, for example in agriculture it is used to produce transgenic plants. Expression vectors have been used to introduce a vitamin A precursor, beta-carotene, into rice plants. This product is called golden rice. This process has also been used to introduce a gene into plants that produces an insecticide, called Bacillus thuringiensis toxin or Bt toxin which reduces the need for farmers to apply insecticides since it is produced by the modified organism. In addition expression vectors are used to extend the ripeness of tomatoes by altering the plant so that it produces less of the chemical that causes the tomatoes to rot. There have been controversies over using expression vectors to modify crops due to the fact that there might be unknown health risks, possibilities of companies patenting certain genetically modified food crops, and ethical concerns. Nevertheless, this technique is still being used and heavily researched. Transgenic animals have also been produced to study animal biochemical processes and human diseases, or used to produce pharmaceuticals and other proteins. They may also be engineered to have advantageous or useful traits. Green fluorescent protein is sometimes used as tags which results in animal that can fluoresce, and this have been exploited commercially to produce the fluorescent GloFish.
Sources: en.wikipedia.org
=== EC 1.21.4 With a disulfide as acceptor === EC 1.21.4.1: D-proline reductase (dithiol) EC 1.21.4.2: glycine reductase EC 1.21.4.3: sarcosine reductase EC 1.21.4.4: betaine reductase EC 1.21.4.5: tetrachlorohydroquinone reductive dehalogenase
== Clinical significance == Erectile dysfunction, the inability to achieve or maintain an erection, is the most common disorder of the penis, and most commonly results from vascular disease. Penile fracture is a rupture of the tunica albuginea caused by severe blunt trauma to the erect penis, which raises cavernosal pressure beyond what the tunica can withstand. Most cases occur during sexual intercourse. During erection the circular fibres of the tunica thin from around 2 mm to about 0.25 mm, and the weakest point lies on the ventral side of the shaft immediately adjacent to the urethra, where most ruptures occur; the urethra is involved in roughly 20% of cases. Buck's fascia normally confines the resulting haematoma and swelling to the penile shaft. Penile fracture is regarded as a urological surgical emergency, as delayed treatment can result in long-lasting sexual dysfunction. In Peyronie's disease, fibrous plaques containing excessive collagen form within the tunica albuginea, causing focal inelasticity and curvature of the penis. The condition is usually benign but may be associated with painful erections or erectile dysfunction. Its underlying pathogenesis is not known, although evidence suggests that repeated microtrauma leads to fibrin deposition from microvascular injury. Priapism is a prolonged, rigid erection occurring in the absence of appropriate stimulation, conventionally defined as one lasting four hours or longer and not relieved by ejaculation.
Bodybuilding developed in the late 19th century, promoted in England by the German Eugen Sandow, now considered as the "Father of Modern Bodybuilding". He allowed audiences to enjoy viewing his physique in "muscle display performances". Although audiences were thrilled to see a well-developed physique, the men simply displayed their bodies as part of strength demonstrations or wrestling matches. Sandow had a stage show built around these displays through his manager, Florenz Ziegfeld. The Oscar-winning 1936 musical film The Great Ziegfeld depicts the beginning of modern bodybuilding, when Sandow began to display his body for carnivals. Sandow was so successful at flexing and posing his physique that he later created several businesses around his fame, and was among the first to market products branded with his name. He was credited with inventing and selling the first exercise equipment for the masses: machined dumbbells, spring pulleys, and tension bands. Even his image was sold by the thousands in "cabinet cards" and other prints.
=== Mechanism of action === Hydroxychloroquine increases lysosomal pH in antigen-presenting cells by two mechanisms: As a weak base, it is a proton acceptor and via this chemical interaction, its accumulation in lysozymes raises the intralysosomal pH, but this mechanism does not fully account for the effect of hydroxychloroquine on pH. Additionally, in parasites that are susceptible to hydroxychloroquine, it interferes with the endocytosis and proteolysis of hemoglobin and inhibits the activity of lysosomal enzymes, thereby raising the lysosomal pH by more than two orders of magnitude over the weak base effect alone. In 2003, a novel mechanism was described wherein hydroxychloroquine inhibits stimulation of the toll-like receptor (TLR) 9 family receptors. TLRs are cellular receptors for microbial products that induce inflammatory responses through activation of the innate immune system. As with other quinoline antimalarial drugs, the antimalarial mechanism of action of quinine has not been fully resolved. The most accepted model is based on hydrochloroquinine and involves the inhibition of hemozoin biocrystallization, which facilitates the aggregation of cytotoxic heme. Free cytotoxic heme accumulates in the parasites, causing death. Hydroxychloroquine increases the risk of low blood sugar through several mechanisms. These include decreased clearance of the hormone insulin from the blood, increased insulin sensitivity, and increased release of insulin from the pancreas.
to produce immune cells to fight antigens, to remove particulate matter and aged blood cells, mainly red blood cells, and to produce blood cells during fetal life. The spleen synthesizes antibodies in its white pulp and removes antibody-coated bacteria and antibody-coated blood cells by way of blood and lymph node circulation. The white pulp of the spleen provides immune function due to the lymphocytes housed there. The spleen also consists of red pulp, which is responsible for getting rid of aged red blood cells and pathogens. This is carried out by macrophages present in the red pulp. A study published in 2009 using mice found that the spleen contains, in its reserve, half of the body's monocytes within the red pulp. These monocytes, upon moving to injured tissue (e.g., the heart), turn into dendritic cells and macrophages while promoting tissue healing. The spleen is a center of activity of the mononuclear phagocyte system. It can be considered analogous to a large lymph node, as its absence causes a predisposition to certain infections. Notably, the spleen is essential for a multitude of functions. The spleen removes pathogens and old erythrocytes from the blood (red pulp) and produces lymphocytes for immune response (white pulp). The spleen is also responsible for recycling some erythrocyte components and discarding others. For example, hemoglobin is broken down into amino acids, which are reused. Research on bony fish has shown that a high concentration of T cells is found in the spleen's white pulp. Like the thymus, the spleen has only efferent lymphatic vessels.
Sources: en.wikipedia.org
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.
Research material is commonly offered at 95 percent purity or above by chromatographic area, with some suppliers listing 98 percent. Higher grades usually carry a higher price and are chosen when the assay is sensitive to trace impurities.
Mass spectrometry is the standard check, often paired with amino acid analysis or peptide mapping. A chromatographic retention time alone is generally considered insufficient for structural confirmation.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.